E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
metastatic malignant melanoma |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10025671 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10027480 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to compare the following regimens with respect to antitumor activity in patients who are previously untreated with cytotoxic chemotherapy for metastatic malignant melanoma: ABI-007 150 mg/m2 Days 1, 8, and 15 every 4 weeks Dacarbazine 1000 mg/m2 every 3 weeks |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives of this study are to compare the safety and tolerability of the 2 treatments; evaluate the pharmacokinetic parameters; and to analyze secreted protein acidic and rich in cysteine (SPARC) and other molecular biomarkers in tumor tissue and peripheral blood and to determine their possible correlation with efficacy outcomes. |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
FARMACOGENETICA: Versione:Emend.3 Data:2009/04/15 Titolo:Biomarkers tumorali ed Esiti clinici in pazienti con Melanoma Metastatico Maligno
Tumor Biomarkers and Clinical Outcome in Patients with Metastatic Malignant Melanoma Obiettivi:L`obiettivo primario di questo sottostudio e` di valutare i livelli di espressione di proteine SPARC ed esaminare la sua correlazione alla risposta della terapia con ABI-007
|
|
E.3 | Principal inclusion criteria |
1. Histologically or cytologically confirmed cutaneous malignant melanoma with evidence of metastasis (Stage IV). 2. No prior cytotoxic chemotherapy for metastatic malignant melanoma is permitted. Prior treatment with kinase inhibitors or cytokines is permitted. No prior adjuvant cytotoxic chemotherapy is permitted. Prior adjuvant therapy with interferon, GM-CSF and/or vaccines is permitted. 3. Male or non-pregnant and non-lactating female, and ≥ 18 years of age. If a female patient is of child-bearing potential, as evidenced by regular menstrual periods, she must have a negative serum pregnancy test (�-hCG) within 72 hours prior to first study drug administration. If sexually active, the patient must agree to utilize contraception considered adequate and appropriate by the investigator. 4. No other current active malignancy within the past 3 years. 5. Radiographically-documented measurable disease (defined by the presence of at least 1 radiographically documented measurable lesion [see Section ‎8.3.1.1 for definition of measurable lesions]). 6. Patient has the following blood counts at Baseline: - ANC  1.5 x 109 cells/L; - platelets  100 x 109 cells/L; - Hgb  9 g/dL. 7. Patient has the following blood chemistry levels at Baseline: - AST (SGOT), ALT (SGPT)  2.5x upper limit of normal range (ULN); ≤ 5.0 xULN if hepatic metastases present; - total bilirubin ≤ ULN; - creatinine  1.5 mg/dL. - LDH ≤ 2.0 x ULN 8. Expected survival of > 12 weeks. 9. ECOG performance status 0-1. 10. Patient or his/her legally authorized representative or guardian has been informed about the nature of the study, and has agreed to participate in the study, and signed the Informed Consent form prior to participation in any study-related activities. |
|
E.4 | Principal exclusion criteria |
1. History of or current evidence of brain metastases, including leptomeningeal involvement. 2. Patient has pre-existing peripheral neuropathy of NCI CTCAE Scale of Grade ≥ 2. 3. Prior radiation to a target lesion is permitted only if there has been clear progression of the lesion since radiation was completed. 4. Patient has a clinically significant concurrent illness. 5. Patient is, in the investigator�s opinion, unlikely to be able to complete the study through the End of Study (EOS) visit. 6. Patient is currently enrolled, or will enroll in a different clinical study in which investigational therapeutic procedures are performed or investigational therapies are administered while participating in this study. Marker studies or studies evaluating biological correlates are permitted. 7. Patient has serious medical risk factors involving any of the major organ systems such that the investigator considers it unsafe for the patient to receive an experimental research drug. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy endpoint is progression-free survival (PFS) based on a blinded radiology assessment. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 9 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 54 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
L`ultima visita dell`ultimo paziente e` la definizione di fine dello studio. Dopo l`ultima visita di ciascun paziente lo stato globale di sopravvivenza deve essere monitorato su base mensile per 6 mesi e quindi ogni 3 mesi per un totale di 2 anni |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |